{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:14:08Z","timestamp":1789874048129,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbmt.2015.09.016","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T02:30:54Z","timestamp":1443753054000},"page":"2039-2051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood\u00a0and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Sergio","family":"Giralt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosta","family":"Gahrton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paremesweran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gimsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Garcia-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-2913","authenticated-orcid":false,"given":"Hans Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turreson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gasparreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"LeMaistre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.09.016_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.016_bib2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-03-211953","article-title":"Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols","volume":"114","author":"Hoering","year":"2009","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2015.09.016_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1179\/102453312X13336169154971","article-title":"Multiple myeloma: treatment evolution","author":"San Miguel","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2015.09.016_bib4","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Avet-Loiseau","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/bbmt.2003.50002","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review","volume":"9","author":"Hahn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet Loiseau","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.2008.07454.x","article-title":"The prognostic significance of 8p21 deletion in multiple myeloma","volume":"144","author":"Sutlu","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12032-013-0489-8","article-title":"8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma","volume":"30","author":"Gmid\u00e8ne","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib10","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1053\/j.seminhematol.2012.05.003","article-title":"Management strategies for relapsed\/refractory multiple myeloma: current clinical perspectives","volume":"49","author":"Jakubowiak","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bbmt.2015.09.016_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.016_bib13","first-page":"609","article-title":"Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry","volume":"87","author":"Alegre","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.016_bib14","first-page":"1228","article-title":"Intensive therapy for multiple myeloma in patients younger than 60 years. Long term results focusing on the effect of the degree of response and relapse pattern after transplantation","volume":"91","author":"Lenhoff","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.016_bib15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib16","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.016_bib17","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.016_bib18","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM 010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.016_bib19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib20","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib21","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib22","first-page":"3522","article-title":"Phase I study of 30 minute infusion of carfilzomib as single agent or in combination with low dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"32","author":"Papadopoulos","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.016_bib24","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood.V116.21.3049.3049","article-title":"Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed\/refractory multiple myeloma (mm): updated efficacy and safety data after >2 years of follow-up","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib25","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib26","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose expansion study of PX-171-006 of carfilzomib, lenalidomide, and low dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib28","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.016_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomized, double blind phase 3 trial","volume":"11","author":"San Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.016_bib32","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1002\/cncr.26662","article-title":"Durable remission with salvage second auto-transplants in patients with multiple myeloma","volume":"118","author":"Shah","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.09.016_bib33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SC is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3109\/10428194.2011.575967","article-title":"Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation","volume":"52","author":"Fenk","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.09.016_bib36","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.016_bib37","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.bbmt.2011.12.146","article-title":"Outcomes following salvage autologous stem cell transplant for multiple myeloma","volume":"18","author":"Silva Rondon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib38","first-page":"1","article-title":"Second auto stem cell transplant for treatment of relapsed multiple myeloma","volume":"10","author":"Gonzalvez","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib39","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Savage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib40","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.28104","article-title":"Autologous retransplantation for patients with recurrent multiple myeloma. A single-center experience with 200 patients","volume":"119","author":"Sellner","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.09.016_bib41","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/bmt.2015.39","article-title":"Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT","volume":"50","author":"Gr\u00f6vdal","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/bmt.2015.125","article-title":"Salvage bortezomib-dexamethasone and high dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM and ASCT. A phase-2 trial","volume":"50","author":"Gimsing","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib44","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"10","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.016_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/bmt.2013.187","article-title":"Second transplants for multiple myeloma relapsing after a previous autotransplant\u2014reduced-intensity allogeneic versus autologous transplantation","volume":"49","author":"Freytes","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbmt.2011.07.026","article-title":"Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability","volume":"18","author":"Patriarca","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/bmt.2008.22","article-title":"Reduced-intensity conditioning allogeneic SCT as a salvage treatment for relapsed multiple myeloma","volume":"41","author":"De Lavallade","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib48","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bmt.1701208","article-title":"Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft","volume":"21","author":"Mehta","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib49","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.09.016_bib50","first-page":"174","article-title":"Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation","volume":"5","author":"Wirk","year":"2013","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.bbmt.2015.09.016_bib51","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11899-013-0185-y","article-title":"Allogeneic hematopoietic stem cell transplantation for multiple myeloma: What place, if any?","volume":"8","author":"Giralt","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2015.09.016_bib52","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.hoc.2014.06.001","article-title":"Allogeneic stem cell transplantation for multiple myeloma","volume":"28","author":"Bensinger","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2015.09.016_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2554.2554","article-title":"Allogeneic hematopoietic stem cell transplantation for multiple myeloma: evolution and outcomes over more than two decades within EBMT centers","volume":"124","author":"Michallet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2009.07984.x","article-title":"Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation","volume":"148","author":"Kr\u00f6ger","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib56","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kr\u00f6ger","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kr\u00f6ger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib58","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib59","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib60","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.12410","article-title":"Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients","volume":"162","author":"Caballero-Vel\u00e1zquez","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib61","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bmt.2013.37","article-title":"Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma","volume":"48","author":"Nishihori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib62","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.016_bib63","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2011.051441","article-title":"Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease","volume":"97","author":"Rosinol","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.016_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","article-title":"High dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and\u00a0depth of disease response before autologous transplantation for\u00a0multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.016_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.016_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12885-015-1237-6","article-title":"Predicting response to\u00a0multidrug regimens in cancer patients using cell line experiments\u00a0and regularized regression models","volume":"15","author":"Falgreen","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:02Z","timestamp":1761058382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115006412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1083879115006412"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood\u00a0and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}